ARTICLE | Finance
Truffle’s recipe for company creation
Truffle Capital plans to deploy €250M fund to scour the U.S., Europe for IP to build biotechs, medtechs
December 19, 2019 12:02 AM UTC
Updated on Dec 20, 2019 at 11:12 PM UTC
Paris-based Truffle Capital has closed its €250 million ($277.9 million) BioMedTech fund to create new drug and medtech companies and nurture them through at least Phase II testing.
The fund will channel around 30% of its capital into drug development and 70% into medtech across 10 to 12 companies, mostly in France. Individual investments could range from €4 million to €35 million, with an aim to support each company for up to about eight years. ...